All In Biotech

Drug Trial Radar · NCT02609399

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

Influenza Therapeutic Trial: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency Department to High Risk Subjects

Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Nov 1, 2015

Primary completion

May 26, 2017

Study completion May 31, 2018

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Department of Health and Human Services
First posted
Nov 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study is designed to demonstrate the feasibility of utilizing Emergency Departments (EDs) as a primary site for subject enrollment in clinical trials evaluating influenza therapeutics, and to provide pilot data for future clinical trial design and planning. Primary Objective: To prospectively enroll high-risk subjects with laboratory-confirmed influenza into a randomized, open label study of oral versus IV influenza therapeutic to include symptom evaluation and outcome assessments. Secondary Objective 1: To identify influenza positive patients utilizing a previously established triage-based assessment and rapid testing algorithm for suspected influenza infection. Secondary Objective 2: To retrospectively evaluate all potentially eligible patients for potential enrollment biases. Secondary Objective 3: To create a repository of residual nasopharyngeal samples collected from ED patients with suspected influenza illness.

Conditions

  • Influenza

Interventions

  • OseltamivirDrug

    Oral

  • PeramivirDrug

    IV Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) QuestionnaireTime frame: ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)
  2. Mean Symptom Severity Score During the 2016-2017 Influenza Season for Symptom Domains as Assessed Using the FLU-PRO™ QuestionnaireTime frame: ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)
  3. Mean Karnofsky Performance Scale Score During the 2015-2016 Influenza SeasonTime frame: ED Enrollment Visit through Day 14 ( 2015-2016 influenza season)
  4. Mean Karnofsky Performance Scale Score During the 2016-2017 Influenza SeasonTime frame: ED Enrollment Visit through Day 14 ( 2016-2017 influenza season)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Maricopa Integrated Health System

    Phoenix, Arizona

  • Johns Hopkins Hospital

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.